Allogeneic transplantation for patients with Philadelphia chromosome positive acute lymphoblastic leukemia: Is it imperative in the tyrosine kinase inhibitor era?

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Before the advent of tyrosine kinase inhibitors (TKIs), Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) was associated with dismal survival without allogeneic hematopoietic stem cell transplantation (allo-HSCT). Recent evidence has demonstrated that the combination of TKI and chemotherapy can result in a high rate of complete remission, thereby enabling more patients to proceed to allo-HSCT. However, with more studies reporting non-inferior outcomes with TKI and chemotherapy combination without allo-HSCT, the need for allo-HSCT in Ph+ ALL has become less certain. This review summarizes evidence that will address the relevance of allo-HSCT in Ph+ ALL.

Original languageEnglish (US)
JournalBest Practice and Research: Clinical Haematology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Philadelphia Chromosome
Hematopoietic Stem Cell Transplantation
Homologous Transplantation
Chromosomes
Stem cells
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Protein-Tyrosine Kinases
Chemotherapy
Combination Drug Therapy
Drug Therapy
Survival

Keywords

  • Acute lymphoblastic leukemia
  • ALL
  • allo-HSCT
  • Allogeneic hematopoietic stem cell transplantation
  • Ph+
  • Philadelphia chromosome positive
  • TKI
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Clinical Biochemistry

Cite this

@article{e828117130764bf89fc214153ca58218,
title = "Allogeneic transplantation for patients with Philadelphia chromosome positive acute lymphoblastic leukemia: Is it imperative in the tyrosine kinase inhibitor era?",
abstract = "Before the advent of tyrosine kinase inhibitors (TKIs), Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) was associated with dismal survival without allogeneic hematopoietic stem cell transplantation (allo-HSCT). Recent evidence has demonstrated that the combination of TKI and chemotherapy can result in a high rate of complete remission, thereby enabling more patients to proceed to allo-HSCT. However, with more studies reporting non-inferior outcomes with TKI and chemotherapy combination without allo-HSCT, the need for allo-HSCT in Ph+ ALL has become less certain. This review summarizes evidence that will address the relevance of allo-HSCT in Ph+ ALL.",
keywords = "Acute lymphoblastic leukemia, ALL, allo-HSCT, Allogeneic hematopoietic stem cell transplantation, Ph+, Philadelphia chromosome positive, TKI, Tyrosine kinase inhibitor",
author = "Litzow, {Mark R}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.beha.2018.09.004",
language = "English (US)",
journal = "Best Practice and Research in Clinical Haematology",
issn = "1521-6926",
publisher = "Bailliere Tindall Ltd",

}

TY - JOUR

T1 - Allogeneic transplantation for patients with Philadelphia chromosome positive acute lymphoblastic leukemia

T2 - Is it imperative in the tyrosine kinase inhibitor era?

AU - Litzow, Mark R

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Before the advent of tyrosine kinase inhibitors (TKIs), Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) was associated with dismal survival without allogeneic hematopoietic stem cell transplantation (allo-HSCT). Recent evidence has demonstrated that the combination of TKI and chemotherapy can result in a high rate of complete remission, thereby enabling more patients to proceed to allo-HSCT. However, with more studies reporting non-inferior outcomes with TKI and chemotherapy combination without allo-HSCT, the need for allo-HSCT in Ph+ ALL has become less certain. This review summarizes evidence that will address the relevance of allo-HSCT in Ph+ ALL.

AB - Before the advent of tyrosine kinase inhibitors (TKIs), Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) was associated with dismal survival without allogeneic hematopoietic stem cell transplantation (allo-HSCT). Recent evidence has demonstrated that the combination of TKI and chemotherapy can result in a high rate of complete remission, thereby enabling more patients to proceed to allo-HSCT. However, with more studies reporting non-inferior outcomes with TKI and chemotherapy combination without allo-HSCT, the need for allo-HSCT in Ph+ ALL has become less certain. This review summarizes evidence that will address the relevance of allo-HSCT in Ph+ ALL.

KW - Acute lymphoblastic leukemia

KW - ALL

KW - allo-HSCT

KW - Allogeneic hematopoietic stem cell transplantation

KW - Ph+

KW - Philadelphia chromosome positive

KW - TKI

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85054826451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054826451&partnerID=8YFLogxK

U2 - 10.1016/j.beha.2018.09.004

DO - 10.1016/j.beha.2018.09.004

M3 - Article

C2 - 30466747

AN - SCOPUS:85054826451

JO - Best Practice and Research in Clinical Haematology

JF - Best Practice and Research in Clinical Haematology

SN - 1521-6926

ER -